New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies in use
It is well documented that the Contract Development and Manufacturing Organisation (CDMO) market is booming and demand for contract services is higher than ever before. Concurrently, we are seeing record numbers of new drugs entering development, with a massive acceleration from 2020 onwards.
What is less well reported, however, is how companies are approaching their outsourcing strategies in a marketplace where capacity is so constrained.
As demand for CDMOs outnumbers supply, drug sponsors are being forced to think about outsourcing much earlier than before. Sponsored by Thermo Fisher Scientific, CPHI's latest report calls on experts from across the pharmaceutical industry to shine a light on the challenges companies face when selecting an outsource partner, and divulge their tips for managing these relationships.
Key questions posed by this report include:
Should a drug sponsor work with multiple vendors or opt for an integrated services solution? Hajir Mokhtari, Senior Manager, Program Management at Thermo Fisher Scientific, explains the complexities of managing multiple vendors and stakeholders at once.
How should a drug sponsor maintain oversight? Stephanie Gaulding, Managing Director at Pharmatech Associates, advises drawing up contractual agreements from the offset, such as quality and master service agreements.
Is phase-appropriate development out of date? Bikash Chatterjee, CEO of Pharmatech Associates, argues that a forward-looking IND strategy, which keeps the final submission in mind, will shrink the time it takes to get to market.
How will accelerated pathways change the way you outsource? Valdas Jurkauskas, Senior Vice President at Pardes Biosciences, recommends looking at the CDMO’s process chemistry experience and capabilities.
Click on the link below to read the full report.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance